New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
06:03 EDTAZN, WFMStocks with implied volatility below IV index mean; WFM AZN
Stocks with implied volatility below IV index mean; Whole Foods (WFM) 30, AstraZeneca (AZN) 21 according to iVolatility.
News For AZN;WFM From The Last 14 Days
Check below for free stories on AZN;WFM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2014
10:00 EDTWFMOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:35 EDTWFMWhole Foods downgraded to Underperform from Peer Perform at Wolfe Research
Wolfe Research downgraded Whole Foods to Underperform based on checks that indicate increased promotions and weaker sales trends.
08:21 EDTWFMWhole Foods continues to have share gain opportunities, says Morgan Stanley
Morgan Stanley believes Whole Foods can continue to grow its share within the natural/organic market to 29% in 2018 from 24% in 2013. The firm said Whole Foods benefits from its leading position and sees upside potential to estimates. Shares are Overweight rated with a $50 price target.
05:25 EDTAZNAdams Express, MedImmune announce clinical trial partnership
Advaxis (ADXS) has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca (AZN). The Phase I/II immunotherapy study will evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis' lead cancer immunotherapy vaccine, ADXS-HPV, as a treatment for patients with advanced, recurrent or refractory human papillomavirus, or HPV,-associated cervical cancer and HPV-associated head and neck cancer. Both MEDI4736 and ADXS-HPV are cancer immunotherapies, a new class of treatments that use the body's own immune system to help fight cancer. Under the terms of the agreement, MedImmune and Advaxis will evaluate the combination as a treatment for HPV-associated cervical cancer and squamous cell carcinoma of the head and neck. The Phase I part of the trial is expected to establish a recommended dose regimen of MEDI4736 with ADXS-HPV, and the Phase II portion will assess the safety and efficacy of the combination. The study will be funded and conducted by Advaxis. Results from the study will be used to determine whether further clinical development of this combination is warranted. Under the terms of the deal, MedImmune has a non-exclusive relationship with respect to HPV-driven tumour types. MedImmune has first right of negotiation for future development of combinations involving MEDI4736 and ADXS-HPV.
July 21, 2014
06:15 EDTWFMWhole Foods implied volatility of 43 at upper end of index mean range
July 17, 2014
07:46 EDTWFMWhole Foods share price could get worse before it gets better, says UBS
Subscribe for More Information
July 16, 2014
10:36 EDTAZNTreasury calls on Congress to halt inversion deals
Subscribe for More Information
08:01 EDTAZNAlexion names former AstraZeneca CEO David Brennan to board
Subscribe for More Information
07:59 EDTAZNTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
05:53 EDTWFMWhole Foods implied volatility of 42 at upper end of index mean range
Subscribe for More Information
July 15, 2014
06:05 EDTWFMWhole Foods implied volatility of 40 at upper end of index mean range
Subscribe for More Information
July 13, 2014
15:54 EDTWFMGameStop, TJX, Staples, three other retailers look cheap, Barron's says
Subscribe for More Information
July 11, 2014
11:45 EDTWFMStocks with call strike movement; YHOO WFM
Subscribe for More Information
July 10, 2014
08:53 EDTWFMWhole Foods 2H comps guidance may be too high, says Cantor
Cantor remains concerned about the effects of competitive pricing pressure on Whole Foods. The firm thinks the company could face execution challenges going forward, and it believes that the company's multiple remains too high, given its challenges. The firm cut its price target on the shares to $34 from $38 and keeps a Sell rating on the stock.
July 9, 2014
06:06 EDTWFMWhole Foods implied volatility of 41 at upper end of index mean range

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use